URGENT: The COVID-19 epidemic is severely impacting the progress of ALS research at the ALS Therapy Development Institute. If you are able to give, will you please provide an immediate gift to fund our lab?


TDI 201

This PERK inhibitor is being explored by scientists at the ALS Therapy Development Institute for its ability to modulate the efficacy of the UPR pathway, thereby protecting against neurotoxicity found to play a role in ALS.


Type: Small Molecule
Stage: Active
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

We are in the process of analyzing data produced from a rigorous preclinical survival efficacy study on this small molecule.

Comment on this Topic

(All comments are moderated before they appear here.)